Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hypertension

Management of hypertensive disorders of late pregnancy

New data from a randomized controlled trial suggest that a strategy of expectant monitoring aimed at prolonging pregnancy until 37 weeks of gestation might be preferable to immediate delivery in women with nonsevere hypertensive disorders of late pregnancy. In this study, which included 703 women, the composite incidence of adverse maternal outcomes (including thromboembolic disease and eclampsia) did not differ significantly between the expectant monitoring and immediate delivery groups (3.1% versus 1.1%), whereas the incidence of neonatal respiratory distress syndrome was significantly higher in the immediate delivery group (5.7% versus 1.7%).

References

  1. Broekhuijsen, K. et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 10.1016/S0140-6736(14)61998-X

Download references

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Management of hypertensive disorders of late pregnancy. Nat Rev Nephrol 11, 316 (2015). https://doi.org/10.1038/nrneph.2015.62

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.62

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing